HomeHealthcare & Life Sciences Next-Generation Cancer Therapeutics Market

Global Next-Generation Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Targeted Therapy (Small Molecule Inhibitors)Â , ImmunotherapyÂ Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)Â CAR-T Cell TherapyÂ Cancer VaccinesÂ , Gene TherapyÂ , Cell Therapy (e.g., TILs, NK cells)Â ), By Cancer Type (Lung CancerÂ , Breast CancerÂ , Colorectal CancerÂ , Blood Cancers (Leukemia, Lymphoma, Myeloma)Â ), By Country (North America, Europe, APAC, Middle East and Africa, Latin Ameri

Starting From
USD 3950

Buy Now

Report Benefits

Develop business strategies by understanding the trends shaping and driving the Market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track sales in the global and country-specific Market.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Executive Summary
1. Introduction
Market Introduction
1. Market Definition
2. Scope of the Study
3. Market Structure
Research Methodology
1. Primary Research
2. Research Methodology
3. Assumptions & Exclusions
4. Secondary Data Sources
Market Factor Analysis
1. Value Chain Analysis: Next-Generation Cancer Therapeutics Market
2. Porters Five Forces Analysis
  1. Bargaining Power of Suppliers
  2. Bargaining Power of Buyers
  3. Threat of Substitution
  4. Threat of New Entrants
  5. Competitive Rivalry
Market Dynamics
1. Drivers
2. Restraints
3. Opportunities
Recent Trends Analysis
Impact of COVID-19 on Next-Generation Cancer Therapeutics Market
1. Pre and Post Covid -19 Market Scenario Analysis
2. Market Recovery Timeline and Challenge
3. Measures Taken by Top Players
Regulatory Landscape
Next-Generation Cancer Therapeutics Market, By Therapy Type
1. Introduction
  1. Market Size and Forecast, By Therapy Type
2. Targeted Therapy (Small Molecule Inhibitors)
  1. Market Size and Forecast, By Region
3. Immunotherapy
  1. Market Size and Forecast, By Region
  2. Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)
    1. Market Size and Forecast, By Region
  3. CAR-T Cell Therapy
    1. Market Size and Forecast, By Region
  4. Cancer Vaccines
    1. Market Size and Forecast, By Region
4. Gene Therapy
  1. Market Size and Forecast, By Region
5. Cell Therapy (e.g., TILs, NK cells)
  1. Market Size and Forecast, By Region
6. Antibody-Drug Conjugates (ADCs)
  1. Market Size and Forecast, By Region
7. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
  1. Market Size and Forecast, By Region
Next-Generation Cancer Therapeutics Market, By Cancer Type
1. Introduction
  1. Market Size and Forecast, By Cancer Type
2. Lung Cancer
  1. Market Size and Forecast, By Region
3. Breast Cancer
  1. Market Size and Forecast, By Region
4. Colorectal Cancer
  1. Market Size and Forecast, By Region
5. Blood Cancers (Leukemia, Lymphoma, Myeloma)
  1. Market Size and Forecast, By Region
6. Prostate Cancer
  1. Market Size and Forecast, By Region
7. Brain Cancer (e.g., GBM)
  1. Market Size and Forecast, By Region
8. Pan-Tumor (Tumor-agnostic therapies)
  1. Market Size and Forecast, By Region
Next-Generation Cancer Therapeutics Market, By Modality
1. Introduction
  1. Market Size and Forecast, By Modality
2. Monotherapy
  1. Market Size and Forecast, By Region
3. Combination Therapy
  1. Market Size and Forecast, By Region
  2. Immunotherapy + Targeted Drugs
    1. Market Size and Forecast, By Region
  3. Chemotherapy + ADC
    1. Market Size and Forecast, By Region
  4. mRNA + Checkpoint Inhibitors
    1. Market Size and Forecast, By Region
Next-Generation Cancer Therapeutics Market, By Route of Administration
1. Introduction
  1. Market Size and Forecast, By Route of Administration
2. Intravenous (IV)
  1. Market Size and Forecast, By Region
3. Oral
  1. Market Size and Forecast, By Region
4. Intratumoral / Localized
  1. Market Size and Forecast, By Region
5. Subcutaneous
  1. Market Size and Forecast, By Region
Next-Generation Cancer Therapeutics Market, By Mechanism of Action
1. Introduction
  1. Market Size and Forecast, By Mechanism of Action
2. Immune Activation (Checkpoint Inhibition)
  1. Market Size and Forecast, By Region
3. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
  1. Market Size and Forecast, By Region
4. DNA Damage Response Modulators (e.g., PARP inhibitors)
  1. Market Size and Forecast, By Region
5. Tumor Microenvironment Modulatio
  1. Market Size and Forecast, By Region
6. Apoptosis Induction
  1. Market Size and Forecast, By Region
Next-Generation Cancer Therapeutics Market, By End-User
1. Introduction
  1. Market Size and Forecast, By End-User
2. Specialized Cancer Hospitals
  1. Market Size and Forecast, By Region
3. Academic and Research Institutes
  1. Market Size and Forecast, By Region
4. Ambulatory Infusion Centers
  1. Market Size and Forecast, By Region
5. Homecare (for oral or SC delivery)
  1. Market Size and Forecast, By Region
Regional Overview
1. Introduction
  1. Market Size and Forecast
2. North America
  1. Market Size and Forecast
    1. By Therapy Type
      1. Targeted Therapy (Small Molecule Inhibitors)
      2. Immunotherapy
      3. Gene Therapy
      4. Cell Therapy (e.g., TILs, NK cells)
      5. Antibody-Drug Conjugates (ADCs)
      6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
    2. By Cancer Type
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
      5. Prostate Cancer
      6. Brain Cancer (e.g., GBM)
      7. Pan-Tumor (Tumor-agnostic therapies)
    3. By Modality
      1. Monotherapy
      2. Combination Therapy
    4. By Route of Administration
      1. Intravenous (IV)
      2. Oral
      3. Intratumoral / Localized
      4. Subcutaneous
    5. By Mechanism of Action
      1. Immune Activation (Checkpoint Inhibition)
      2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
      3. DNA Damage Response Modulators (e.g., PARP inhibitors)
      4. Tumor Microenvironment Modulatio
      5. Apoptosis Induction
    6. By End-User
      1. Specialized Cancer Hospitals
      2. Academic and Research Institutes
      3. Ambulatory Infusion Centers
      4. Homecare (for oral or SC delivery)
  2. U.S.
    1. By Therapy Type
      1. Targeted Therapy (Small Molecule Inhibitors)
      2. Immunotherapy
      3. Gene Therapy
      4. Cell Therapy (e.g., TILs, NK cells)
      5. Antibody-Drug Conjugates (ADCs)
      6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
    2. By Cancer Type
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
      5. Prostate Cancer
      6. Brain Cancer (e.g., GBM)
      7. Pan-Tumor (Tumor-agnostic therapies)
    3. By Modality
      1. Monotherapy
      2. Combination Therapy
    4. By Route of Administration
      1. Intravenous (IV)
      2. Oral
      3. Intratumoral / Localized
      4. Subcutaneous
    5. By Mechanism of Action
      1. Immune Activation (Checkpoint Inhibition)
      2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
      3. DNA Damage Response Modulators (e.g., PARP inhibitors)
      4. Tumor Microenvironment Modulatio
      5. Apoptosis Induction
    6. By End-User
      1. Specialized Cancer Hospitals
      2. Academic and Research Institutes
      3. Ambulatory Infusion Centers
      4. Homecare (for oral or SC delivery)
  3. Canada
3. Europe
  1. Market Size and Forecast
    1. By Therapy Type
      1. Targeted Therapy (Small Molecule Inhibitors)
      2. Immunotherapy
      3. Gene Therapy
      4. Cell Therapy (e.g., TILs, NK cells)
      5. Antibody-Drug Conjugates (ADCs)
      6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
    2. By Cancer Type
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
      5. Prostate Cancer
      6. Brain Cancer (e.g., GBM)
      7. Pan-Tumor (Tumor-agnostic therapies)
    3. By Modality
      1. Monotherapy
      2. Combination Therapy
    4. By Route of Administration
      1. Intravenous (IV)
      2. Oral
      3. Intratumoral / Localized
      4. Subcutaneous
    5. By Mechanism of Action
      1. Immune Activation (Checkpoint Inhibition)
      2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
      3. DNA Damage Response Modulators (e.g., PARP inhibitors)
      4. Tumor Microenvironment Modulatio
      5. Apoptosis Induction
    6. By End-User
      1. Specialized Cancer Hospitals
      2. Academic and Research Institutes
      3. Ambulatory Infusion Centers
      4. Homecare (for oral or SC delivery)
  2. U.K.
    1. By Therapy Type
      1. Targeted Therapy (Small Molecule Inhibitors)
      2. Immunotherapy
      3. Gene Therapy
      4. Cell Therapy (e.g., TILs, NK cells)
      5. Antibody-Drug Conjugates (ADCs)
      6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
    2. By Cancer Type
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
      5. Prostate Cancer
      6. Brain Cancer (e.g., GBM)
      7. Pan-Tumor (Tumor-agnostic therapies)
    3. By Modality
      1. Monotherapy
      2. Combination Therapy
    4. By Route of Administration
      1. Intravenous (IV)
      2. Oral
      3. Intratumoral / Localized
      4. Subcutaneous
    5. By Mechanism of Action
      1. Immune Activation (Checkpoint Inhibition)
      2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
      3. DNA Damage Response Modulators (e.g., PARP inhibitors)
      4. Tumor Microenvironment Modulatio
      5. Apoptosis Induction
    6. By End-User
      1. Specialized Cancer Hospitals
      2. Academic and Research Institutes
      3. Ambulatory Infusion Centers
      4. Homecare (for oral or SC delivery)
  3. Germany
  4. France
  5. Spain
  6. Italy
  7. Russia
  8. Nordic
  9. Benelux
  10. Rest of Europe
4. APAC
  1. Market Size and Forecast
    1. By Therapy Type
      1. Targeted Therapy (Small Molecule Inhibitors)
      2. Immunotherapy
      3. Gene Therapy
      4. Cell Therapy (e.g., TILs, NK cells)
      5. Antibody-Drug Conjugates (ADCs)
      6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
    2. By Cancer Type
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
      5. Prostate Cancer
      6. Brain Cancer (e.g., GBM)
      7. Pan-Tumor (Tumor-agnostic therapies)
    3. By Modality
      1. Monotherapy
      2. Combination Therapy
    4. By Route of Administration
      1. Intravenous (IV)
      2. Oral
      3. Intratumoral / Localized
      4. Subcutaneous
    5. By Mechanism of Action
      1. Immune Activation (Checkpoint Inhibition)
      2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
      3. DNA Damage Response Modulators (e.g., PARP inhibitors)
      4. Tumor Microenvironment Modulatio
      5. Apoptosis Induction
    6. By End-User
      1. Specialized Cancer Hospitals
      2. Academic and Research Institutes
      3. Ambulatory Infusion Centers
      4. Homecare (for oral or SC delivery)
  2. China
    1. By Therapy Type
      1. Targeted Therapy (Small Molecule Inhibitors)
      2. Immunotherapy
      3. Gene Therapy
      4. Cell Therapy (e.g., TILs, NK cells)
      5. Antibody-Drug Conjugates (ADCs)
      6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
    2. By Cancer Type
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
      5. Prostate Cancer
      6. Brain Cancer (e.g., GBM)
      7. Pan-Tumor (Tumor-agnostic therapies)
    3. By Modality
      1. Monotherapy
      2. Combination Therapy
    4. By Route of Administration
      1. Intravenous (IV)
      2. Oral
      3. Intratumoral / Localized
      4. Subcutaneous
    5. By Mechanism of Action
      1. Immune Activation (Checkpoint Inhibition)
      2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
      3. DNA Damage Response Modulators (e.g., PARP inhibitors)
      4. Tumor Microenvironment Modulatio
      5. Apoptosis Induction
    6. By End-User
      1. Specialized Cancer Hospitals
      2. Academic and Research Institutes
      3. Ambulatory Infusion Centers
      4. Homecare (for oral or SC delivery)
  3. South Korea
  4. Japan
  5. India
  6. Australia
  7. Singapore
  8. Taiwan
  9. South East Asia
  10. Rest of Asia-Pacific
5. Middle East and Africa
  1. Market Size and Forecast
    1. By Therapy Type
      1. Targeted Therapy (Small Molecule Inhibitors)
      2. Immunotherapy
      3. Gene Therapy
      4. Cell Therapy (e.g., TILs, NK cells)
      5. Antibody-Drug Conjugates (ADCs)
      6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
    2. By Cancer Type
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
      5. Prostate Cancer
      6. Brain Cancer (e.g., GBM)
      7. Pan-Tumor (Tumor-agnostic therapies)
    3. By Modality
      1. Monotherapy
      2. Combination Therapy
    4. By Route of Administration
      1. Intravenous (IV)
      2. Oral
      3. Intratumoral / Localized
      4. Subcutaneous
    5. By Mechanism of Action
      1. Immune Activation (Checkpoint Inhibition)
      2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
      3. DNA Damage Response Modulators (e.g., PARP inhibitors)
      4. Tumor Microenvironment Modulatio
      5. Apoptosis Induction
    6. By End-User
      1. Specialized Cancer Hospitals
      2. Academic and Research Institutes
      3. Ambulatory Infusion Centers
      4. Homecare (for oral or SC delivery)
  2. UAE
    1. By Therapy Type
      1. Targeted Therapy (Small Molecule Inhibitors)
      2. Immunotherapy
      3. Gene Therapy
      4. Cell Therapy (e.g., TILs, NK cells)
      5. Antibody-Drug Conjugates (ADCs)
      6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
    2. By Cancer Type
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
      5. Prostate Cancer
      6. Brain Cancer (e.g., GBM)
      7. Pan-Tumor (Tumor-agnostic therapies)
    3. By Modality
      1. Monotherapy
      2. Combination Therapy
    4. By Route of Administration
      1. Intravenous (IV)
      2. Oral
      3. Intratumoral / Localized
      4. Subcutaneous
    5. By Mechanism of Action
      1. Immune Activation (Checkpoint Inhibition)
      2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
      3. DNA Damage Response Modulators (e.g., PARP inhibitors)
      4. Tumor Microenvironment Modulatio
      5. Apoptosis Induction
    6. By End-User
      1. Specialized Cancer Hospitals
      2. Academic and Research Institutes
      3. Ambulatory Infusion Centers
      4. Homecare (for oral or SC delivery)
  3. Turky
  4. Saudi Arabia
  5. South Africa
  6. Egypt
  7. Nigeria
  8. Rest of MEA
6. LATAM
  1. Market Size and Forecast
    1. By Therapy Type
      1. Targeted Therapy (Small Molecule Inhibitors)
      2. Immunotherapy
      3. Gene Therapy
      4. Cell Therapy (e.g., TILs, NK cells)
      5. Antibody-Drug Conjugates (ADCs)
      6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
    2. By Cancer Type
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
      5. Prostate Cancer
      6. Brain Cancer (e.g., GBM)
      7. Pan-Tumor (Tumor-agnostic therapies)
    3. By Modality
      1. Monotherapy
      2. Combination Therapy
    4. By Route of Administration
      1. Intravenous (IV)
      2. Oral
      3. Intratumoral / Localized
      4. Subcutaneous
    5. By Mechanism of Action
      1. Immune Activation (Checkpoint Inhibition)
      2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
      3. DNA Damage Response Modulators (e.g., PARP inhibitors)
      4. Tumor Microenvironment Modulatio
      5. Apoptosis Induction
    6. By End-User
      1. Specialized Cancer Hospitals
      2. Academic and Research Institutes
      3. Ambulatory Infusion Centers
      4. Homecare (for oral or SC delivery)
  2. Brazil
    1. By Therapy Type
      1. Targeted Therapy (Small Molecule Inhibitors)
      2. Immunotherapy
      3. Gene Therapy
      4. Cell Therapy (e.g., TILs, NK cells)
      5. Antibody-Drug Conjugates (ADCs)
      6. RNA-based Therapy (mRNA, siRNA, ASO, LNA, etc.)
    2. By Cancer Type
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Blood Cancers (Leukemia, Lymphoma, Myeloma)
      5. Prostate Cancer
      6. Brain Cancer (e.g., GBM)
      7. Pan-Tumor (Tumor-agnostic therapies)
    3. By Modality
      1. Monotherapy
      2. Combination Therapy
    4. By Route of Administration
      1. Intravenous (IV)
      2. Oral
      3. Intratumoral / Localized
      4. Subcutaneous
    5. By Mechanism of Action
      1. Immune Activation (Checkpoint Inhibition)
      2. Oncogene Targeting (e.g., BRAF, KRAS, EGFR)
      3. DNA Damage Response Modulators (e.g., PARP inhibitors)
      4. Tumor Microenvironment Modulatio
      5. Apoptosis Induction
    6. By End-User
      1. Specialized Cancer Hospitals
      2. Academic and Research Institutes
      3. Ambulatory Infusion Centers
      4. Homecare (for oral or SC delivery)
  3. Mexico
  4. Argentina
  5. Chile
  6. Colombia
  7. Rest of LATAM
Competitive Landscape, 2025
1. Introduction
2. Next-Generation Cancer Therapeutics Market Share Analysis, 2025 (%)
  1. Market Share Analysis, 2025
  2. Competition Ranking, 2025
  3. Key Developments & Growth Strategies
    1. Merger & Acquisition
    2. Product Launch
    3. Expansion
  4. Consolidated SWOT Analysis of Key Players
Company Profile
1. Merck & Co., Inc.
  1. Business Overview
  2. Financial Data
  3. Key Product Categories
  4. Recent Developments
2. Bristol Myers Squibb
3. Roche
4. AstraZeneca
5. Novartis
6. Pfizer
7. Johnson & Johnson
8. Gilead Sciences
9. Amgen
10. Eli Lilly and Company
11. Daiichi Sankyo
12. Sanofi
13. Regeneron Pharmaceuticals
14. AbbVie
15. Moderna

Report Benefits

Table of Contents